Back to top

Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion

As previously reported, Leerink downgraded Gilead (GILD) to Market Perform from Outperform with a price target of $127, down from $146. The firm, w...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Gilead Sciences, Inc. (GILD)

General Mills, Inc. (GIS)